Related Experiment Video

Updated: Jun 9, 2026

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal

F L Day1, J Desai, C L Corless

  • 1Department of Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Melbourne, VIC 8006, Australia. fday@med.usyd.edu.au.

Medical Oncology (Northwood, London, England)
|August 28, 2010
PubMed

Insights

Wild type gastrointestinal stromal tumors (GIST) resistant to imatinib were treated with an anti-insulin-like growth factor 1 receptor (IGF-1R) antibody. The treatment was ineffective, suggesting IGF-1R expression levels are crucial for therapy success.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Wild type (WT) gastrointestinal stromal tumors (GIST) lack KIT or PDGFRα mutations, rendering them less responsive to imatinib therapy.
  • These WT GISTs are hypothesized to rely on signaling pathways involving the insulin-like growth factor 1 receptor (IGF-1R).

Observation:

  • A case study of a 29-year-old woman with neurofibromatosis type 1-associated WT GIST is presented.
  • The patient received treatment with a monoclonal antibody targeting IGF-1R.

Findings:

  • The anti-IGF-1R antibody treatment proved ineffective in this patient.
  • Tumor IGF-1R expression levels were measured and discussed as a potential factor influencing treatment response.

Implications:

  • This case suggests that IGF-1R expression levels may be a critical determinant of treatment efficacy for WT GIST.
  • Future clinical trials should prospectively assess tumor IGF-1R expression to correlate with outcomes in anti-IGF-1R therapies.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...